Aim: To describe the design of the SOUL trial (Semaglutide cardiOvascular oUtcomes triaL) and the baseline clinical data of its participants. Materials and methods: In SOUL, the effects of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, on the risk of cardiovascular (CV) events in individuals with type 2 diabetes and established …You may want to research a person you are planning to have a business or personal relationship with. You can use the Internet to research a person's background and history. Free on...Background: This meta-analysis aimed to combine the data available from clinical trials to assess the effects of subcutaneous and oral semaglutide administration on glycemic control, weight management, and safety outcomes in patients with type 2 diabetes (T2D). Methods: We systematically searched for phase 3 randomized …In STEP 2 (individuals with overweight or obesity, and type 2 diabetes), mean weight loss was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo from baseline to week 68. Improvements in cardiometabolic risk factors, including high blood pressure, atherogenic lipids and benefits on physical function and quality of life were seen with ...Materials and methods: AE analyses pooled data from the Semaglutide Treatment Effect in People With Obesity (STEP) 1-3 trials for participants randomized to 68 weeks' semaglutide 2.4 mg (N = 2117 ...Rybelsus. Rybelsus Online is a convenient and accessible рlatform that allows individuals with type 2 diabetes to easily access and obtаin their prescription medication. With the advent of digital technology аnd online pharmаcies, Rybelsus can now be ordered and delivered to your doorstep with just a few clicks.Dermatologic findings associated with semaglutide use: A scoping review. Dermatologic findings associated with semaglutide use: A scoping review J Am Acad Dermatol. 2024 Mar 29:S0190-9622(24)00532-2. doi: 10.1016/j.jaad.2024.03.021. Online ahead of print. Authors Megan M Tran 1 ...Apr 19, 2023 · Semaglutide’s availability as a long-acting formulation offers advantages in SMI, where medication non-adherence is a larger issue compared to other medical conditions. 45,46 Patients have also reported better quality of life and treatment satisfaction with once-weekly semaglutide in comparison to other drugs within the same drug class. 47 ...Abstract. Oral semaglutide (Rybelsus ®) is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with 94% homology to human GLP-1.It is the first GLP-1RA developed for oral administration, and it comprises a co-formulation of the peptide semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, which overcomes the challenges of peptide absorption in the ...Comments: -Poorly controlled diabetes during pregnancy is associated with both maternal and fetal risks. -When pregnancy is recognized for a women on Wegovy, this drug should be discontinued and the patient should be advised of the risk to a fetus. -Women of childbearing potential should be encouraged to use contraception during therapy; if ...In June of 2021, the US Food and Drug Administration (FDA) approved the drug semaglutide for chronic weight management under the brand name Wegovy, ushering in a new era of obesity treatment. Since then, demand for Wegovy and the type 2 diabetes therapy Ozempic—which contains the same drug and has commonly been prescribed off-label for weight loss—have outpaced production, causing ongoing ...As the FDA explains, semaglutide is a GLP-1 receptor agonist, a medication that mimics a natural hormone called GLP-1 that is released in the gastrointestinal tract in response to eating. GLP-1 ...Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen.Mar 3, 2023 · The effectiveness and safety of oral semaglutide in T2DM were studied in this systematic review and meta-analysis. Semaglutide 7 and 14 mg showed a larger reduction in HbA1c levels, body weight, FPG, SMPG, SBP and HbA1c of less 7.0% when compared to placebo.Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 receptor agonist). It has been approved as a second line treatment option for better glycaemic control in type 2 diabetes and currently under scrutiny for anti-obesity purpose. Semaglutide has been proved to be safe in adults ...Medicine Matters Sharing successes, challenges and daily happenings in the Department of Medicine Thank you to everyone who participated in the 2022 Department of Medicine & Whitin...Once weekly semaglutide at a dose of 2.4 mg administered subcutaneously is a potent glucagon-like peptide 1 receptor agonist that is approved for long-term weight management and has previously ...1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, China; Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a conventional anti-obesity drug systematically in obese or overweight ...Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial - The …Introduction: Recently, the European Medicines Agency (EMA) received reports of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide. Research design and methods: Herein, we sought to evaluate suicidality associated with all GLP-1 RAs relative to other glucose-lowering …semaglutide (t 1/2,semaglutide,day 10) was ~ 1 w eek, showing that, unlike initial absorption, the metabolism and elimination 982 Reviews in Endocrine and Metabolic Disorders (2022) 23:979–994Mar 28, 2024 · Semaglutide, Heart Failure, and Diabetes. 2024-04-18. DOI: 10.1056/NEJMdo007462 ... New research findings are summarized in a short video. Video Summary of. Original Article; Mar 28, 2024;The present study confirms the effectiveness and tolerability of OW semaglutide in a high CV risk real-world cohort of patients with uncontrolled T2DM. In this predominantly GLP1-RA naïve patients, starting OW semaglutide translated into marked benefits on HbA1c (about 1% decrease after 6 months, sustained at 12 months), and weight (-3.5 Kg).Review the mechanism of action of GLP-1RAs in obesity; Introduce semaglutide and summarize the design of the STEP 1–5 trials; Explore the efficacy and safety profile of semaglutide 2.4 mg in the STEP 1–5 trials; …Review Manager 5.4.1 and RStudio were used for the statistical analysis, and RoB-2 (Cochrane) to assess the risk of bias. Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 ...Semaglutide is a medication that has been used to improve blood sugar control in adults with type 2 diabetes. It is available as an injection (given by shot) or by tablet (taken by mouth). The injectable form is sold under the brand name Ozempic®. The tablet form is sold under the brand name Rybelsus®.Purpose This meta-analysis aimed to assess the efficacy and safety of once-weekly semaglutide among adults with overweight or obesity. Methods We searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity. The primary outcomes …weekly subcutaneous semaglutide 2.4 mg (a glucagon-like peptide-1 analogue) in. people with overweight or obesity. Across STEP 1, 3, 4 and 8, semaglutide 2.4 mg. was associated with mean weight losses of 14.9%-17.4% in individuals with over-. weight or obesity without type 2 diabetes from baseline to week 68; 69%-79% of.1 INTRODUCTION. On March 20, 2019, Novo Nordisk, Inc., submitted for the Agency's review New Drug Application (NDA) 213182 RYBELSUS (semaglutide) tablets, for oral use. The proposed indication is to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus (T2DM) (b) (4)TikTok video from The A-List Clinic Weight Loss (@thealistclinic): "SAF Research gives out research #semaglutide meds. We don't! Ours is the real deal #wegovy #ozempic #weightloss #weightlossmeds #californiaweightloss". Doesn't look too bad | WAIT THEY'RE RESEARCH MEDS NOT INTENDED FOR HUMAN USE? | Make sure you get the legit …What is known and objective: The purpose of this review paper is to review the ef-ficacy and safety of subcutaneous semaglutide, marketed as Wegovy, a glucagon- like peptide- 1 receptor agonist for obesity management. Methods: A MEDLINE search (1970 to June 2021) was conducted to identify Phase 3 trials of subcutaneous semaglutide for obesity ...1. zavenrains • 6 mo. ago. Well I ended up taking another 0.25 dose the following day after my first dose and I definitely felt the common symptoms within a few hrs of the 2nd shot. Didn't eat much for two days. After that 48hrs all sides including satiation subsided. Obviously it is too soon to tell if product is dosed accurately since sides ...RESEARCH APPLICATION NUMBER: 209637Orig1s000 SUMMARY REVIEW . NDA 209637 OZEMPIC (semaglutide) Cross Discipline Team Leader Review CDER Cross Discipline Team Leader Review Template 2015 Edition Version date: June 9, 2015. For initial rollout (NME/original BLA reviews) 2 Review Team:The purpose of this review is to provide an analysis of these trials. The GLP-1 RA head-to-head clinical studies have demonstrated that all GLP-1 RA agents are effective therapeutic options at reducing A1C. However, differences exist in terms of magnitude of effect on A1C and weight as well as frequency of adverse effects. Keywords: GLP-1 ...4 Saf Research Semaglutide Mixing Instructions 2022-08-19 practice tips and thorough coverage of this expertly-written reference. Treatment of Non-infectious Uveitis is the ideal reference for all ophthalmologists who seek to improve their understanding of the causes of uveitis and learn how to best treat this condition. Medical Management of ...The broadening application of glucagon-like peptide (GLP)-1 receptor agonists, specifically semaglutide (Ozempic) for the management of diabetes and obesity brings a critical need to evaluate its safety profile, considering estimates of up to 20 million prescriptions per year in the US until 2035. This systematic review aims to assess the incidence of thyroid cancer and detail the spectrum of ...Introduction: Recently, the European Medicines Agency (EMA) received reports of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide. Research design and methods: Herein, we sought to evaluate suicidality associated with all GLP-1 RAs relative to other glucose-lowering …Review the mechanism of action of GLP-1RAs in obesity; Introduce semaglutide and summarize the design of the STEP 1–5 trials; Explore the efficacy and safety profile of semaglutide 2.4 mg in the STEP 1–5 trials; …Cross-Discipline Team Leader Review. Start at 2.5 mg subcutaneously once weekly. After 4 weeks, increase the dose to 5 mg once weekly. If needed, dose increases can be made in 2.5 mg increments after a minimum of …Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater in people who experience GI AEs than those who do not. A previous mediation analysis of the SUSTAIN 1–5 trials indicated minor contribution of nausea/vomiting to the greater WL …Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have attracted much attention because of their significant hypoglycemic and weight-loss …Oral semaglutide 25 mg and 50 mg were superior to 14 mg in reducing HbA 1c and bodyweight in adults with inadequately controlled type 2 diabetes. No new safety concerns were identified. Funding. Novo …Introduction. Obesity is a metabolic disease, which is related to a variety of chronic diseases in addition to affecting the quality of life [].Recent statistics indicate that overweight/obesity and its relentless global rise, with the number of people with excess body weight reaching > 2 billion, approximately 30% of the world population [].Findings. 71 patients were enrolled between June 18, 2019, and April 22, 2021; 49 (69%) patients were female and 22 (31%) were male. Patients had a mean age of 59·5 years (SD 8·0) and mean BMI of 34·9 kg/m 2 (SD 5·9); 53 (75%) patients had diabetes. 47 patients were randomly assigned to the semaglutide group and 24 to the placebo group. After 48 weeks, there was no statistically ...Glucagon-like peptide- 1 receptor analogs (GLP-1RAs) are incretin mimetics with potent glucose-dependent insulinotropic action that translates to glycemic control in people with type- -2 diabetes mellitus (T2DM). These agents potentially have the ability to stimulate proliferation or prevent apoptosis of pancreatic β-cells, induce weight-loss ...Semaglutide is a GLP‐1 analogue shown to reduce energy intake, reduce hunger and increase feelings of satiety and fullness. 19 , 36 This effect has been shown to arise via GLP‐1 receptor activation in the central nervous system, with further indirect modulation of neuronal activity involved in appetite regulation and food intake and …Semaglutide-treated participants, compared with placebo, were also more likely to lose at least 10%, 15% or 20% of baseline body weight at week 104 (P < 0.0001 for the OR for the 10% and 15% ...A conceptual definition is the underlying understanding of something that is necessary to attain before understanding how it is used or applied. In science, it is necessary to unde...In fact, a 2021 phase 3 clinical trial found that 2.4 milligram weekly semaglutide injections produced a mean weight loss of 14.9% (versus 2.4% with a placebo) after 68 weeks in people with a body ...Changes in HbA1c from baseline (mean 8·2%) to week 26 were dose-dependent with oral semaglutide (mean change −1·1% [SE 0·1] for oral semaglutide 3 mg, −1·5% [0·1] for 7 mg, and −1·7% ...Buy Peptides for Scientific Research and Development. ... Semaglutide (GLP-1 Analogue) 6mg. $185.00 As low as: $165.00. Add to Cart. FREE Shipping; ... All customers represent and warrant that through their own review and study that they are fully aware and knowledgeable about the following:Table 1 Baseline demographics, patients characteristics and efficacy of oral semaglutide vs. placebo or active comparators in randomized controlled trials. 17-26. PIONEER-117 PIONEER-218 PIONEER ...Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis October 2023 Diabetology & Metabolic Syndrome 15(1)Clinical Review Report: Semaglutide (Ozempic) (Novo Nordisk Canada Inc.) Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment) CADTH Common Drug Review.After decades of efforts and research, oral semaglutide, the first oral GLP-1RA, is recently being developed and is now available for use in routine clinical practice. ... (−0.3% [95% CI: −0.4%, −0.1%]). Semaglutide was superior compared with liraglutide and placebo with regard to change in body weight at 26 weeks, with a ... A review on ...The Role of SAF Research in Semaglutide. SAF research has shed light on the potential of semaglutide to promote satiety and fullness, leading to improved weight management and glycemic control. Studies have shown that semaglutide can significantly reduce body weight and HbA1c levels in patients with type 2 diabetes and obesity.Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are highly effective at lowering hemoglobin A1c (HbA1c) and facilitating weight loss. Four agents in the GLP-1 RA class, albiglutide, liraglutide, dulaglutide, and semaglutide, also have cardioprotective effects. However, subcutaneous administration of these agents remains a major reason for their underutilization. A new coformulation of ...In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, semaglutide was superior to placebo in improving heart failure-related symptoms and physical limitations, and reducing bodyweight in participants with obesity-related heart failure with preserved ejection fraction. These effects were largely consistent across patient demographic and clinical characteristics ...1/27/2019. Condition: Other. Overall rating 3.3. Effectiveness. Ease of Use. Satisfaction. in study for weight loss using this drug. Lots of side effects: nausea, gas, heartburn. You feel full most of time, less appetite, uncomfortable if you eat to much or to greasy.The purpose of this review is to provide an analysis of these trials. The GLP-1 RA head-to-head clinical studies have demonstrated that all GLP-1 RA agents are effective therapeutic options at reducing A1C. However, differences exist in terms of magnitude of effect on A1C and weight as well as frequency of adverse effects. Keywords: GLP-1 ...Heart failure with preserved ejection fraction accounts for nearly half of heart failure cases.1 Despite the heterogeneous nature of the disease, a uniform treatment has predominantly been used, which has shown benefits in heart failure with reduced ejection fraction but is less efficacious in heart failure with preserved ejection fraction. SGLT2 inhibitors are the only disease-modifying drugs ...A review of these results at a later date would be advisable for future discussions on semaglutide’s efficacy. No direct comparison of 2.4 mg semaglutide with other FDA-approved weight loss medications was made during STEP 1 through 5. This would be a fruitful avenue for future research on pharmacotherapeutics for weight reduction.Saf Research Semaglutide Mixing Instructions Downloaded from dev.mabts.edu by guest PIERRE ISAIAH ADME Processes in Pharmaceutical Sciences Springer Nature Recent developments in nanoparticle and microparticle delivery systems are revolutionizing delivery systems in the food industry. These developments have the potential to solve many of the1 INTRODUCTION. The ongoing obesity pandemic has been a serious public health challenge that threatens individuals, society, and the economies of both developed and developing countries. 1, 2 It is specifically a major problem for women because of their smaller stature and excess weight gain during each pregnancy. 3 In 2015, the estimated overall prevalence of obesity was 12.0% among adults ...The novel anti-obesity medication semaglutide 2.4 mg injected subcutaneously once weekly as an adjunct to a reduced-calorie diet and physical activity helps patients achieve average losses of 9.6-17.4% of initial body weight at week 68, as well as improvements in cardiometabolic and psychosocial indices. ... Review MeSH terms Adult Body WeightAbstract Oral semaglutide (Rybelsus®) is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with 94% homology to human GLP-1. It is the first GLP-1RA developed for oral administration, and it comprises a co-formulation of the peptide semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, which overcomes the challenges of peptide absorption in the ...Anavar 20mg twice daily (verified by a lab test to be real anavar) Semaglutide 1 time per week .125mL / 0.25mg (prescribed) Rauwolscine GM Brand 1 cap per day pre workout. Injectable L Carnitine .5mL / 250mg pre workout (prescribed) My routine was lifting 3 days a week and doing cardio 3-4 days per week for 45 minutes to 1 hour, switching ...Between Aug 4, 2014, and Sept 3, 2015, we randomly assigned 1089 participants to treatment; the mITT population consisted of 362 participants assigned to 0·5 mg semaglutide, 360 to 1·0 mg semaglutide, and 360 to insulin glargine. 49 (14%) participants assigned to 0·5 mg semaglutide discontinued treatment prematurely, compared with 55 (15%) assigned to 1·0 mg semaglutide, and 26 (7% ...Data Synthesis: Once-weekly injectable semaglutide 2.4 mg is indicated as an adjunct to a reduced-calorie diet and increased exercise for chronic weight management in adults with a body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 with at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia.Oral semaglutide can be considered for use either early or late in the T2D treatment continuum. In this review, we consider the clinical evidence for its use in settings in which an injectable GLP-1RA or insulin would traditionally have been recommended, and discuss how best to integrate oral semaglutide into clinical practice in this setting.Aim: To describe the design of the SOUL trial (Semaglutide cardiOvascular oUtcomes triaL) and the baseline clinical data of its participants. Materials and methods: In SOUL, the effects of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, on the risk of cardiovascular (CV) events in individuals with type 2 diabetes and established atherosclerotic CV disease (ASCVD) and ...Semaglutide's availability as a long-acting formulation offers advantages in SMI, where medication non-adherence is a larger issue compared to other medical conditions. 45,46 Patients have also reported better quality of life and treatment satisfaction with once-weekly semaglutide in comparison to other drugs within the same drug class. 47 ...A Review on the Efficacy and Safety of Oral Semaglutide Drugs R D. 2021 Jun;21 ... 1 East Coast Institute for Research, LLC, 3550 University Blvd. South, Suite 101, Jacksonville, FL, 32216, USA. ... subcutaneous semaglutide, dulaglutide, and liraglutide, that also have an indication for reducing major adverse cardiovascular events in patients ...Clinical review of subcutaneous semaglutide for obesity. J Clin Pharm Ther 2022;47(2):184-93. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. ... Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior ...The purpose of this review paper is to review the efficacy and safety of subcutaneous semaglutide, marketed as Wegovy, a glucagon-like peptide-1 receptor agonist for obesity management. Methods A MEDLINE search (1970 to June 2021) was conducted to identify Phase 3 trials of subcutaneous semaglutide for obesity management.I am still trying to figure out how to reply to a specific person. The original person was questioning saf. This is my experience. I have ordered 3 vials of 10mg terzepatide and 1 vial of 15mg. I have lost 18 pounds since March the 28th when I started this. I have also been on a strict diet and moderate exercise.Request PDF | Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes | Background and aims To assess the safety ...Saf Research Semaglutide Mixing Instructions Downloaded from dev.mabts.edu by guest PIERRE ISAIAH ADME Processes in Pharmaceutical Sciences Springer Nature Recent developments in nanoparticle and microparticle delivery systems are revolutionizing delivery systems in the food industry. These developments have the potential to solve many of theThis review details the efficacy and safety profile of semaglutide in the SUSTAIN 1–5 and 7 trials, and its cardiovascular safety profile in the SUSTAIN 6 trial. …Semaglutide User Reviews & Ratings. Brand names: Ozempic, Wegovy, Rybelsus. Semaglutide has an average rating of 6.6 out of 10 from a total of 1,977 reviews on Drugs.com. 54% of reviewers reported a positive experience, while 25% reported a negative experience. Condition.Diabetes, Obesity & Metabolism is an interdisciplinary journal for clinical & experimental pharmacology and therapeutics relating to metabolic & endocrine disease.semaglutide. The study also includes a literature review of the 25 most cited documents on semaglutide. Review Materials and methods Search Strategy and Study Selection Process An online electronic search was performed on 14 August 2023 in the Scopus database to identify the research done on semaglutide. The search term used was semaglutide.BPMP Provinsi Gorontalo. Beranda; Profil Menu Toggle. Sejarah; Visi Dan Misi; Tugas Dan Fungsi; Struktur Organisasi; FasilitasGlucagon-like peptide 1 receptor agonists (GLP-1 RAs) are highly effective at lowering hemoglobin A1c (HbA1c) and facilitating weight loss. Four agents in the GLP-1 RA class, albiglutide, liraglutide, dulaglutide, and semaglutide, also have cardioprotective effects. However, subcutaneous administration of these agents remains a major reason for ...Semaglutide peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide is a glucagon like peptide-1 receptor agonist with cardiovascular benefits for the management of type 2 diabetes. Rev Endocr Metab Disord .... Saf Research Semaglutide Mixing Instructions 1 Saf Research SThe Role of SAF Research in Semaglutide. SAF resear Semaglutide is typically prescribed at a higher dose for weight loss than for type 2 diabetes. The injectable weekly dose used for weight loss is 2.4 milligrams (mg), while the injectable weekly dose used for diabetes ranges between 0.5 and 2 mg. Semaglutide causes significantly more weight loss than placebo according to a clinical trial ...Methods. This open-label study examined the effects of semaglutide on Binge Eating Scale (BES) scores in individuals with BED. Patients were divided into three groups: those prescribed semaglutide, those prescribed either lisdexamphetamine or topiramate, and those prescribed a combination of semaglutide with lisdexamphetamine or topiramate. At the licensed health care practitioner& Semaglutide is a newly available glucagon-like peptide 1 receptor ago-. nist (GLP-1 RA) for the treatment of type 2 diabetes mellitus (T2DM). Subcutaneous semaglutide administered once weekly has ...Science Bio tends to be cheaper than PureRawz in terms of pricing, with a 30 ml bottle of Ostarine costing $44.99. This compares to $54.48 for a 35 ml bottle of Ostarine from PureRawz. PureRawz vs Behemoth Labz. is among the oldest SARMs companies in the marketplace, having been around for close to 30 years. Company Details. SAF Research, also known as Swole AF Labs and SAF Pep...
Continue Reading